{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:58:16Z","timestamp":1783576696604,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T00:00:00Z","timestamp":1565395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T00:00:00Z","timestamp":1565395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00259-019-04434-0","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T05:05:23Z","timestamp":1565413523000},"page":"2545-2557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-7385","authenticated-orcid":false,"given":"Sangeeta Ray","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Lisok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il","family":"Minn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Brummet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Boinapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Ngen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Wharram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Brayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,10]]},"reference":[{"key":"4434_CR1","first-page":"241","volume":"59","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Quarterly J Nucl Med Mol Imaging. 2015;59:241\u201368.","journal-title":"Quarterly J Nucl Med Mol Imaging"},{"key":"4434_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","volume":"22","author":"U Haberkorn","year":"2016","unstructured":"Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22:9\u201315.","journal-title":"Clin Cancer Res"},{"key":"4434_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.urolonc.2012.04.016","volume":"31","author":"JR Osborne","year":"2013","unstructured":"Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31:144\u201354.","journal-title":"Urol Oncol"},{"key":"4434_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2967\/jnumed.117.203570","volume":"59","author":"RA Salas Fragomeni","year":"2018","unstructured":"Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59:871\u20137.","journal-title":"J Nucl Med"},{"key":"4434_CR5","first-page":"2674","volume":"5","author":"SS Chang","year":"1999","unstructured":"Chang SS, O\u2019Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674\u201381.","journal-title":"Clin Cancer Res"},{"key":"4434_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","volume":"70","author":"A Baccala","year":"2007","unstructured":"Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385\u201390.","journal-title":"Urology"},{"key":"4434_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.juro.2017.08.079","volume":"199","author":"S Spatz","year":"2018","unstructured":"Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, et al. Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol. 2018;199:370\u20137.","journal-title":"J Urol"},{"key":"4434_CR8","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"4434_CR9","doi-asserted-by":"publisher","first-page":"128ra39","DOI":"10.1126\/scitranslmed.3003651","volume":"4","author":"J Hrkach","year":"2012","unstructured":"Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4:128ra39.","journal-title":"Sci Transl Med"},{"key":"4434_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","volume":"43","author":"F Sterzing","year":"2016","unstructured":"Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. 68Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4434_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2967\/jnumed.115.163782","volume":"57","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, et al. Comparison of prostate-specific membrane antigen\u2013based 18F-DCFBC PET\/CT to conventional imaging modalities for detection of hormone-na\u00efve and castration-resistant metastatic prostate cancer. J Nucl Med. 2016;57:46\u201353.","journal-title":"J Nucl Med"},{"key":"4434_CR12","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00259-018-4089-x","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Sch\u00e4fers M, B\u00f6gemann M, et al. Diagnostic performance of 18F-PSMA-1007 PET\/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2055\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4434_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Benesova","year":"2015","unstructured":"Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914\u201320.","journal-title":"J Nucl Med"},{"key":"4434_CR14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","volume":"56","author":"M Weineisen","year":"2015","unstructured":"Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169\u201376.","journal-title":"J Nucl Med"},{"key":"4434_CR15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA radioligand therapy for prostate cancer. J Nucl Med. 2017;58:1196\u2013200.","journal-title":"J Nucl Med"},{"key":"4434_CR16","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a 124I\/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4434_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2967\/jnumed.118.214379","volume":"59","author":"T Langbein","year":"2018","unstructured":"Langbein T, Chausse G, Baum RP. Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies. J Nucl Med. 2018;59:1172\u20133.","journal-title":"J Nucl Med"},{"key":"4434_CR18","doi-asserted-by":"publisher","first-page":"17S","DOI":"10.2967\/jnumed.116.186775","volume":"58","author":"K Kopka","year":"2017","unstructured":"Kopka K, Bene\u0161ov\u00e1 M, Ba\u0159inka C, Haberkorn U, Babich J. Glu\u2013ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med. 2017;58:17S\u201326S.","journal-title":"J Nucl Med"},{"key":"4434_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ijc.2910620511","volume":"62","author":"JK Trover","year":"1995","unstructured":"Trover JK, Beckett ML, Wright GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552\u20138.","journal-title":"Int J Cancer"},{"key":"4434_CR20","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1021\/jm400823w","volume":"56","author":"S Ray Banerjee","year":"2013","unstructured":"Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, et al. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem. 2013;56:6108\u201321.","journal-title":"J Med Chem"},{"key":"4434_CR21","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1021\/jm401921j","volume":"57","author":"SR Banerjee","year":"2014","unstructured":"Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Anderson CJ, et al. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014;57:2657\u201369.","journal-title":"J Med Chem"},{"key":"4434_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Schaefer M, Bauder-Wuest U, Hull W-E, Waengler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688\u201397.","journal-title":"Bioconjug Chem"},{"key":"4434_CR23","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.7150\/thno.18719","volume":"7","author":"CJ Choy","year":"2017","unstructured":"Choy CJ, Ling X, Geruntho JJ, Beyer SK, Latoche JD, Langton-Webster B, et al. 177Lu-labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics. 2017;7:1928\u201339.","journal-title":"Theranostics"},{"key":"4434_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","volume":"15","author":"CA Umbricht","year":"2018","unstructured":"Umbricht CA, Benesova M, Schibli R, Muller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297\u2013306.","journal-title":"Mol Pharm"},{"key":"4434_CR25","unstructured":"Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Schlyer D, et al. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging. 2018.2018;45:1841\u20131851."},{"key":"4434_CR26","doi-asserted-by":"crossref","unstructured":"Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, et al. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. J Nucl Med. 2015;56:628\u201334.","DOI":"10.2967\/jnumed.114.149062"},{"key":"4434_CR27","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1021\/jm801055h","volume":"51","author":"Y Chen","year":"2008","unstructured":"Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambahatla M, Fox JJ, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008;51:7933\u201343.","journal-title":"J Med Chem"},{"key":"4434_CR28","doi-asserted-by":"crossref","unstructured":"Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-targeted alpha-particle radiopharmaceutical therapy. J Nucl Med. 2016;57:1569\u201375.","DOI":"10.2967\/jnumed.116.174300"},{"key":"4434_CR29","doi-asserted-by":"publisher","first-page":"9167","DOI":"10.1002\/anie.201102872","volume":"50","author":"SR Banerjee","year":"2011","unstructured":"Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, et al. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed. 2011;50:9167\u201370.","journal-title":"Angew Chem Int Ed"},{"key":"4434_CR30","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/acs.bioconjchem.5b00679","volume":"27","author":"S Ray Banerjee","year":"2016","unstructured":"Ray Banerjee S, Chen Z, Pullambhatla M, Lisok A, Chen J, Mease RC, et al. Preclinical comparative study of 68Ga-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA. Bioconjug Chem. 2016;27:1447\u201355.","journal-title":"Bioconjug Chem"},{"key":"4434_CR31","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2967\/jnumed.115.155929","volume":"56","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC, et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen. J Nucl Med. 2015;56:1401\u20137.","journal-title":"J Nucl Med"},{"key":"4434_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jphotobiol.2016.12.018","volume":"167","author":"Y Chen","year":"2017","unstructured":"Chen Y, Chatterjee S, Lisok A, Minn I, Pullambhatla M, Wharram B, et al. A PSMA-targeted theranostic agent for photodynamic therapy. J Photochem Photobiol B Biol. 2017;167:111\u20136.","journal-title":"J Photochem Photobiol B Biol"},{"key":"4434_CR33","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.117.193359","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Stuparu AD, Evans-Axelsson S, Luckerath K, Wei L, Kim W, et al. Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med. 2017;58:1786\u201392.","journal-title":"J Nucl Med"},{"key":"4434_CR34","first-page":"1113","volume":"44","author":"LG Bouchet","year":"2003","unstructured":"Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, et al. MIRD Pamphlet No. 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113\u201347.","journal-title":"J Nucl Med"},{"key":"4434_CR35","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1471-4159.2004.02358.x","volume":"89","author":"RT Olszewski","year":"2004","unstructured":"Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem. 2004;89:876\u201385.","journal-title":"J Neurochem"},{"key":"4434_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/B978-012369454-6\/50053-4","volume-title":"The mouse in biomedical research","author":"C Brayton","year":"2007","unstructured":"Brayton C. Chapter 25 - spontaneous diseases in commonly used mouse strains. In: Fox JG, Davisson MT, Quimby FW, Barthold SW, Newcomer CE, Smith AL, editors. The mouse in biomedical research. second ed. Burlington: Academic; 2007. p. 623\u2013717.","edition":"second"},{"key":"4434_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/0300985811430696","volume":"49","author":"CF Brayton","year":"2012","unstructured":"Brayton CF, Treuting PM, Ward JM. Pathobiology of aging mice and GEM: background strains and experimental design. Vet Pathol. 2012;49:85\u2013105.","journal-title":"Vet Pathol"},{"key":"4434_CR38","first-page":"46","volume":"42","author":"LM Serfilippi","year":"2003","unstructured":"Serfilippi LM, Pallman DR, Russell B. Serum clinical chemistry and hematology reference values in outbred stocks of albino mice from three commonly used vendors and two inbred strains of albino mice. Contemp Top Lab Anim Sci. 2003;42:46\u201352.","journal-title":"Contemp Top Lab Anim Sci"},{"key":"4434_CR39","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1021\/jm800111u","volume":"51","author":"SR Banerjee","year":"2008","unstructured":"Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504\u201317.","journal-title":"J Med Chem"},{"key":"4434_CR40","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1021\/jm400823w","volume":"56","author":"S Ray Banerjee","year":"2013","unstructured":"Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, et al. Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem. 2013;56:6108\u201321.","journal-title":"J Med Chem"},{"key":"4434_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148\u201358.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4434_CR42","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2967\/jnumed.118.207993","volume":"59","author":"D Ta\u00efeb","year":"2018","unstructured":"Ta\u00efeb D, Foletti J-M, Bardi\u00e8s M, Rocchi P, Hicks RJ, Haberkorn U. PSMA-targeted radionuclide therapy and salivary gland toxicity: why does it matter? J Nucl Med. 2018;59:747\u20138.","journal-title":"J Nucl Med"},{"key":"4434_CR43","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted alpha therapy of mCRPC with 225Actinium-PSMA-617: dosimetry estimate and empirical dose finding. J Nucl Med. 2017;58:1624\u201331.","DOI":"10.2967\/jnumed.117.191395"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04434-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04434-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04434-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T23:53:13Z","timestamp":1596930793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04434-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,10]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04434-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,10]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Drs. Banerjee and Pomper are co-inventors on one or more U.S. patents covering compounds discussed in this submission, and as such are entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. No other authors have declared any relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal studies were carried out in compliance with the regulations of the Johns Hopkins Animal Care and Use Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}